Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use.
Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, Zhang F, Wang R, Klompas M, CDC Prevention Epicenters Program. · 2020
Read Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. by Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, Zhang F, Wang R, Klompas M, CDC Prevention Epicenters Program. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7163409.txt.
Introduction
Rhee and co-authors measure antibiotic resistance in sepsis and the costs of mistargeted first treatment, in JAMA Network Open. Their cohort covered 17,430 adults with culture-proven sepsis at 104 United States hospitals. Guidelines urge immediate broad-spectrum antibiotics for suspected sepsis, but how often resistant bacteria are truly present was unclear.
Broad-spectrum drugs were given to 67.0% of patients, yet resistant Gram-positive organisms appeared in only 13.6% and resistant Gram-negative ones in 13.2%. Both missing the true organism and covering resistant organisms that were not there were tied to higher mortality after risk adjustment. The authors argue for faster diagnostics to aim the first dose better.
Catalog record
| CREATOR | Rhee C, Kadri SS, Dekker JP, Danner RL, Chen HC, Fram D, Zhang F, Wang R, Klompas M, CDC Prevention Epicenters Program. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use By Chanu Rhee, Sameer S. Kadri, John P. Dekker, Robert L. Danner, Huai-Chun Chen, David Fram, Fang Zhang, Rui Wang, Michael Klompas Published in: JAMA Network Open DOI: 10.1001/jamanetworkopen.2020.2899 ABSTRACT Key Points Question What is the prevalence of antibiotic resistance in community-onset sepsis, and is there risk associated with the receipt of empiric broad-spectrum antibiotics? Findings In this cohort study of 17 430 adults with culture-positive sepsis admitted to 104 US hospitals, 67.0% received empiric broad-spectrum antibiotics, but resistant gram-positive organisms were isolated in only 13.6% of patients and resistant gram-negative organisms in 13.2%. Both undertreatment (failure to cover organisms) and overtreatment (resistant organisms targeted but not isolated) were associated with higher mortality after detailed risk adjustment. Meaning In this study, broad-spectrum antibiotics were frequently administered to patients with community-onset sepsis without resistant organisms, and these therapies were associated with worse outcomes. INTRODUCTION Sepsis, the syndrome of life-threatening organ dysfunction complicating severe infection, is a leading cause of death in hospitalized patients.1 Early active antibiotic therapy is associated with better outcomes.2,3,4,5 Therefore, national quality measures and international guidelines recommend immediate empiric broad-spectrum antibiotics for all patients with suspected sepsis.6,7 However, it is unclear how many patients presenting with sepsis require coverage for methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and other potentially resistant pathogens. Most existing epidemiologic studies present rates of resistance to selected antimicrobials per pathogen rather than quantifying overall resistance rates across all patients and syndromes associated with sepsis. These data are needed to inform the rational use of antibiotics, given that overuse of broad-spectrum therapy may also confer harm by selecting for antibiotic-resistant bacteria, increasing the risk of adverse events, such as Clostridioides difficile infections, and raising costs.8,9,10,11,12 Overtreatment has also been associated with higher mortality rates in some populations.13,14,15 Therefore, we sought to elucidate the epidemiology of antibiotic-resistant pathogens in patients with culture-positive community-onset sepsis and the risks of both inadequate and unnecessarily broad antibiotic treatments in US hospitals. METHODS Study Design, Data Source, and Population We conducted a retrospective cohort study using Cerner HealthFacts, a deidentified data set that includes detailed electronic clinical data from diverse US hospitals.16,17,18,19,20 We included all patients aged at least 20 years who were admitted between January 2009 and September 2015, excluding those with missing discharge dispositions or International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) rather than ICD-9-CM codes.16 Data analysis took place between January 2018 and December 2019 and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.21 This study was approved by the institutional review board at Harvard Pilgrim Health Care Institute with a waiver of informed consent given that the patients in this study had high mortality rates, making collection of consent infeasible. Identifying Patients With Culture-Positive Sepsis We identified sepsis hospitalizations using the US Centers for Disease Control and Prevention Adult Sepsis Event surveillance criteria, which defines sepsis as concurrent evidence of presumed serious infection (ie, blood culture order and ≥4 consecutive days of new antibiotics) and organ dysfunction (ie, initiation of vasopressors or mechanical ventilation, lactate level ≥2.0 mmol/L [to convert to milligram per deciliter, divide by 0.111], doubling in baseline creatinine level or ≥50% decrease in estimated glomerular filtration rate, doubling in total bilirubin level to ≥2.0 mg/dL [to convert to micromoles per liter, multiply by 17.104], or ≥50% decrease in platelet count to <100 × 103/μL [to convert to × 109/L, multiply by 1.0]).22 We focused on culture-positive community-onset sepsis, as defined by a blood culture draw, first antibiotic administration, organ dysfunction, and clinical cultures obtained and subsequently testing positive for potentially pathogenic organisms, all on hospital day 2 or earlier. We excluded culture-negative patients because of the difficulty determining antibiotic appropriateness in this population using electronic data alone. We further excluded patients transferred from hospitals, rehabilitation or long-term facilities, and hospice as well as patients with hospital-onset sepsis because the epidemiology, antibiotic resistance patterns, and recommended treatments differ substantially in health care–acquired vs community-acquired infections.23,24,25 Infectious syndromes were classified using ICD-9-CM discharge codes (eAppendix 1 in the Supplement).26 Culture Sites and Pathogens of Interest We included clinical cultures from the following anatomic sites: blood, respiratory, urine, deep tissue, central nervous system fluid, body fluid, and superficial tissue. We focused on pathogens commonly encountered in routine practice. Gram-negative organisms included Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Proteus species, P aeruginosa, and Serratia species. Gram-positive organisms included S aureus, Streptococcus species, and Enterococcus species. Surveillance cultures and cultures positive for other organisms within the first 2 days of hospitalization were excluded, including coagulase-negative Staphylococcus species (because it can be difficult to distinguish contaminants vs true infections) and Enterococcus species isolated from respiratory samples. We assessed the prevalence of the following resistant organisms: MRSA, vancomycin-resistant Enterococcus (VRE), extended spectrum β-lactamase (ESBL) gram-negative organisms (ie, resistant to all β-lactams except carbapenems), carbapenem-resistant Enterobacteriaceae (CRE; defined as resistant to imipenem, meropenem, doripenem, or ertapenem), and ceftriaxone-resistant gram negatives (CTX-RO; including P aeruginosa and ESBLs). We grouped P aeruginosa with other CTX-RO organisms because they share the need for treatment with β-lactams with anti-Pseudomonal coverage, which are an important class of broad-spectrum antibiotics. Antibiotic Susceptibilities and Adequacy of Therapy We assessed each potential antibiotic-pathogen combination using antibiotic susceptibilities derived from in vitro reports generated by each institution. Intermediate susceptibilities were treated as nonsusceptible. In some cases, susceptibilities to specific antibiotics administered were not explicitly listed but could be assumed using knowledge of the spectrum of activity for each antibiotic-pathogen combination. For example, many antibiotics are intrinsically inactive against certain species (eg, ceftriaxone vs P aeruginosa) and are therefore not included in susceptibility reports. Alternatively, a gram-negative organism susceptible to ceftriaxone may not have susceptibilities reported to all higher-generation cephalosporins (ie, cefepime), but these agents can be safely used. We created rules to impute susceptibilities for each antibiotic-pathogen combination (eAppendix 2 in the Supplement). We considered patients to have received inadequate empiric therapy if at least 1 pathogen isolated from any clinical culture site was not susceptible to all antibiotics administered on the first and second day of treatment. We considered patients to have received unnecessarily broad empiric therapy if they received adequate empiric therapy and anti-MRSA antibiotics (ie, vancomycin, linezolid, or daptomycin), anti-VRE antibiotics (ie, linezolid or daptomycin), anti-Pseudomonal β-lactams (ie, ceftazidime, cefepime, piperacillin-tazobactam, aztreonam, imipenem, meropenem, or doripenem), or carbapenems (ie, imipenem, meropenem, doripenem, or ertapenem), but none of the organisms targeted by these antibiotics (ie, MRSA, VRE, CTX-RO, or ESBL) were recovered. We did not consider CRE in the analysis of unnecessarily broad therapy given the infrequency of empiric CRE treatment.27 Outcomes We examined associations of both inadequate and unnecessarily broad empiric regimens with in-hospital mortality. The analysis of unnecessarily broad antibiotics was limited to patients who received adequate antibiotics because an empiric regimen would generally not be considered unnecessarily broad if the spectrum was inadequate. Secondary outcomes included hospital-onset acute kidney injury, defined as an increase in creatinine level by at least 0.5 mg/dL (to convert to micrograms per liter, multiply by 1) at any point during hospitalization relative to the initial value on presentation and